The FDA approved Vanda Pharmaceuticals’ oral tradipitant (Nereus) for prevention of vomiting induced by motion, marking the first new prescription motion‑sickness drug in more than 40 years. Approval followed three pivotal studies, including two phase III real‑world trials with patients on boats, and triggered a strong market reaction. Vanda said Nereus will launch in the coming months; its approval creates a new commercial product in an underserved indication and offers a potential revenue stream in 2026. Investors reacted immediately, sending Vanda shares sharply higher on the approval news.